Neuroimmunology in Clinical Practice - part 4 pot

76 BERNADETTE KALMAN ET AL. disease-modifying treatment in MS: What do we need and what can we expect in the future? J Neurol, 251(5), V57–64. Kappos, L., Moeri, D., Radue, E.W. et al. 1999. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet, 353, 964–9. Keegan, M., Konig, F., McClelland, R. et al. 2005. Relation between humoral pathologic changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet, 366, 579–82. Keiper, M.D., Grossman, R.I., Hirsch, J.A. et al. 1998. MR identification of white matter abnormalities in multiple sclerosis: A comparison between 1.5 T and 4 T. AJNR Am J Neuroradiol, 19, 1489–93. Keir, G.L.R. and Thompson, E.J. 1990. Isoelectric focusing of cerebrospinal fluid immunoglobulin G: An annotated update. Ann Clin Biochem, 27, 436–43. Kellar-Wood, H., Robertson, N., Govan, G.G., Compston, D.A.S. and Harding, A.E. 1994. Leber’s hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. Ann Neurol, 36, 109–12. Kenealy, S.J., Herrel, L.A., Bradford, Y. et al. 2006. Examination of seven candidate regions for multiple sclerosis: strong evidence of linkage to chromosome 1q44. Genes Immun, 7, 73–6. Khoshyomn, S., Braff, S.P. and Penar, P.L. 2002. Tumefactive multiple sclerosis plaque. Neurological picture. J Neurol Neurosurg Psychiatry, 73, 85. Kinnunen, E., Juntunen, J., Ketonen, L. et al., 1988. Genetic susceptibility to multiple sclerosis: A co-twin study of a nation-wide series. Arch Neurol, 45, 1108–11. Koike, F., Satoh, J., Miyake, S. et al. 2003. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol, 139, 109–18. Korn-Lubetzki, I., Kahana, E., Cooper, G. and Abramsky, O. 1984. Activity of multiple sclerosis during pregnancy and puerperium. Ann Neurol, 16, 229–31. Kornek, B. and Lassmann, H. 2003. Neuropathology of multiple sclerosis – new concepts. Brain Res Bull, 61, 321–6. Kremenchutzky, M., Cottrell, D., Rice, G. et al. 1999. The natural history of multiple sclerosis: A geo- graphically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re- evaluation. Brain, 122(10), 1941–50. Kremenchitzky, M., Rice, G.P.A., Baskerville, J., Wingerchuck, D.M. and Ebers, G.C. 2006. The natural history of multiple sclerosis: A geographic- ally based study 9: Observations on the progressive phase of the disease. Brain, 129, 584–94. Krupp, L.B. 2004. Fatigue in Multiple Sclerosis. A Guide to Diagnosis and Management. Demos Medical Publishing Inc., New York. Krupp, L.B., Christodoulou, C., Melville, P., Scherl, W.F., MacAllister, W.S. and Elkins, L.E. 2004. Donepezil improved memory in multiple sclerosis in a random- ized clinical trial. Neurology, 63(9), 1579–85. Kuokkanen, S., Sundvall, M., Terwilinger, J.D. et al. 1996. A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2. Nature Genet, 13, 477–80. Kuokkanen, S., Gschwend, M., Rioux, J.D. et al. 1997. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet, 61, 1379–87. Kurdi, A., Ayesh, I., Abdallat, A. and Maayta, U. 1977. Different B lymphocyte alloantigens associated with multiple sclerosis in Arabs and Northern Europeans. Lancet, i, 1123–5. Kuroiwa, Y., Shibasaki, H. and Ikeda, M. 1983. Prevalence of multiple sclerosis and its north to south gradient in Japan. Neuroepidemiol, 2, 62–9. Kurtzke, J.F. 1975a. A reassessment of the distribution of multiple sclerosis. Part One. Acta Neurol Scand, 51, 110–36. Kurtzke, J.F. 1975b. A reassessment of the distribution of multiple sclerosis. Part Two. Acta Neurol Scand, 51, 137–57. Kurtzke, J.F. 1993. Epidemiologic evidence for mul- tiple sclerosis as an infection. Clin Microbiol Rev, 6, 382–427. Kurtzke, J.F. 2005. Epidemiology and etiology of multiple sclerosis. Phys Med Rehab Clin N Am, 16327–49. Kutzelnigg, A., Lucchinetti, C.F., Stadelmann, C. et al. 2005. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain, 128, 2705–12. La Rocca, N.G. 2000. Cognitive and emotional disorders. In J.S. Burks and K.P. Johnson (eds.), Multiple Sclerosis. Diagnosis, Medical Management, and Rehabilitation, Demos, New York, pp. 405–21. Lassmann, H. 2005. Multiple sclerosis pathology: Evolution of pathogenetic concepts. Brain Pathology, 15, 217–22. Lassmann, H., Raine, C.S., Antel, J. and Prineas, J.W. 1998. Immunopathology of multiple sclerosis: Report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuro- immunol, 86, 213–17. Laule, C., Vavasour, I.M., Whittall, K.P. et al. 2003. Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol, 250, 924–31. Lee, F., MacDonald, A M. and Aldren Turner, J.W. 1964. Leber’s disease with symptoms resembling disseminated sclerosis. J Neurol Neurosurg Psychiatry, 27, 415–21. Leyva, L., Fernandez, O., Fedetz, M. et al. 2005. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol, 163, 165–71. Li, D.K., Held, U., Petkau, J. et al. 2006. MRI T2 lesion burden in multiple sclerosis: A plateauing NICP_C03 04/05/2007 12:26PM Page 76 Multiple sclerosis 77 relationship with clinical disability. Neurology, 66, 1384–9. Liblau, R., van Endert, P.M., Sandberg-Wollheim, M. et al. 1993. Antigen processing gene polymorph- isms in HLA-DR2 multiple sclerosis. Neurology, 43, 1192–7. Ligers, A., Dyment, D.A., Willer, C.J. et al.; Canadian Collaborative Study Groups. 2001. Evidence of linkage with HLA-DR in DRB1*15-negative families with multiple sclerosis. Am J Hum Genet, 9, 900–3. Limburg, C.C. 1950. The geographic distribution of multiple sclerosis and its estimated prevalence in the United States. Proc Assoc Res Nerv Ment Dis, 28, 15–24. Lindberg, R.L., De Groot, C.J., Certa, U. et al. 2004. Multiple sclerosis as a generalize CNS disease- comperative microarray analysis of normal appear- ing white matter and lesions in secondary progressive MS. J Neuroimmunol, 152, 154–67. Lincoln, M.R., Montpetit, A., Cader, M.Z. et al. 2005. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet, 37, 1108–12. Link, H. and Tibbling, G. 1977. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest, 37, 397– 40. Lublin, F.D. 2005. Clinical features and diagnosis of multiple sclerosis. Neurologic Clinics, 23, 1–15. Lublin, F.D. and the Hu 23F2G MS Study Group. 1999. A Phase II trial of anti-cd11/cd18 monoclonal anti- body in acute exacerbations of multiple sclerosis. Neurology, 52, A290. Lublin, F.D. and Reingold, S.C. 1996. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology, 46, 907–11. Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M. and Lassmann, H. 2000. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol, 47, 707–17. Lucchinetti, C.F., Bruck, W., Rodriguez, M. and Lassmann, H. 1996. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathology, 6, 259–74. Lucchinetti, C.F., Parisi, J. and Bruck, W. 2005. The pathology of multiple sclerosis. Neurol Clin, 23, 77–105. Lynch, S.G., Rose, J.W., Petajan, J.H., Stauffer, D., Kamerath, C. and Leppert, M. 1991. Discordance of T-cell receptor β-chain genes in familial multiple sclerosis. Ann Neurol, 30, 402–10. Lynch, S.G., Rose, J., Petajan, J.H. and Leppert, M. 1992. Discordance of the T cell receptor alpha-chain in familial multiple sclerosis. Neurology, 42, 839–44. Malfroy, R., Viratelle, C., Coppin, H., Borot, N. and Roth, M.P. 1995. Polymorphic tri- and tetranu- cleotide repeats in exon 1 and 8 of the myelin oligo- dendrocyte glycoprotein (MOG) gene. Hum Genet, 96, 737–8. Mandel, M., Gurevich, M., Pauzner, R., Kaminski, N. and Achiron, A. 2004. Autoimmunity gene expres- sion portrait: specific signature that intersects or differentiates multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol, 138, 164–70. Mao-Draayer, Y. and Panitch, H. 2004. Alexia without agraphia in multiple sclerosis: Case report with magnetic resonance imaging localization. Mult Scler, 10, 705–7. Marburg, O. 1906. Die sogennante “acute Multiple Sklerosis” (Encephalomyelitis periaxialis scleroticans). J Psychiat Neurol, 27, 211–312. Marrosu, M.G., Muntoni, F., Murru, M.R. et al. 1988. Sardinian multiple sclerosis is associated with HLA- DR4: A serologic and molecular analysis. Neurology, 38, 1749–53. Matsumoto, J., Morrow, D., Kaufman, K. et al. 2001. Surgical therapy for tremor in multiple sclerosis: An evaluation of outcome measures. Neurology, 57(10), 1876–82. McAlpine, D. 1961. The benign form of multiple sclerosis. A study based on 241 cases seen within 3 years of onset and follow up until the tenth year or more of the disease. Brain, 84, 186–203. McDonald, W.I., Compston, A., Edan, G. et al. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol, 50, 121–7. McDougall, A.J. and McLeod, J.G. 2003. Autonomic nervous system function in multiple sclerosis. J Neurol Sci, 215, 79–85. McLeod, J., Hammond, S. and Hallpike, J. 1994. Epidemiology of multiple sclerosis in Australia. Med J Aust, 160, 117–22. Mertens, C., Brassat, D., Reboul, J. et al. 1998. A systemic study of oligodendrocyte growth factors as candidates for genetic susceptibility to MS. Neurology, 51, 748–53. Mi, S., Miller, R.H., Lee, X. et al. 2005. LINGO-1 neg- atively regulates myelination by oligodendrocytes. Nat Neurosci, 8, 745–51. Michailova, S., Ivanova, M., Mihaylova, A., Quin, L., Mikova, O. and Naumova, E. 2005. Pro- and anti- inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J Neuro- immunol, 168, 138–43. Miller, D., Hammond, S., McLeod, J., Purdie, G. and Skegg, D.C. 1990. Multiple sclerosis in Australia and New Zealand: Are the determinants genetic or environmental? J Neurol Neurosurg Psychiatry, 53, 903–5. Miller, D.H., Barkhof, F., Frank, J.A., Parker, G.J. and Thompson, A.J. 2002. Measurement of atrophy in NICP_C03 04/05/2007 12:26PM Page 77 78 BERNADETTE KALMAN ET AL. multiple sclerosis: pathologic basis, methodological aspects and clinical relevance. Brain, 125, 1676–95. Miller, D.H., Khan, O.A., Sheremata, W.A. et al.; International Natalizumab Multiple Sclerosis Trial Group. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 348, 15–23. Miller, D.M., Weinstock-Guttman, B., Bethoun, F. et al. 2000. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler, 6(4), 267–73. Minneboo, A., Uitdehaag, B.M., Ader, H.J., Barkhof, F., Polman, C.H. and Castelijns, J.A. 2005. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology, 65, 56–61. Monson, N.L., Brezinschek, H.P., Brezinschek, R.I. et al. 2005. Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J Neuroimmunol, 158, 170–81. Montalban, X. 2005. Primary progressive multiple sclerosis. Curr Opin Neurol, 18, 261–6. Morales, Y., Parisi, J.E. and Lucchinetti, C.F. 2006. The pathology of multiple sclerosis: Evidence for heterogeneity. Adv Neurol, 98, 27–45. Morgen, K., Jeffries, N.O., Stone, R. et al. 2001. Ring- enchancement in multiple sclerosis: Marker of dis- ease severity. Mult Scler, 7, 167–71. Moseley, I.F., Miller, D.H. and Gass, A. 1998. The contribution of magnetic resonance imaging to the assessment of optic nerve and spinal cord involvement in multiple sclerosis. J Neurol Neurosurg Psychiatry, 64(1), S15–20. MS Council for Clinical Practice Guidelines. 1998. Fatigue in Multiple Sclerosis, Paralyzed Veterans Association, Washington, DC. Mumford, C.J., Wood, N.W., Kellar-Wood, H., Thorpe, J.W., Miller, D.H. and Compston, D.A. 1994. The British Isles survey of multiple sclerosis in twins. Neurology, 44, 11–15. Naito, C., Kuroiwa, Y., Itoyama, T. et al. 1978. HLA and Japanese multiple sclerosis. Tissue Antigens, 12, 19–24. Narayana, P.A. 2005. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging, 15, 46S–57S. Narayanan, S., Francis, S.J., Sled, J.G. et al. 2006. Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal- appearing white matter. Neuroimage, 29, 637–42. Nelson, N., Eeg-Olofsson, O., Larsson, L. and Öhman, S. 1986. The diagnostic and predictive value of cere- brospinal fluid lactate in children with meningitis. Its relation to current diagnostic methods. Acta Pediatr Scand, 75, 52–7. Newcombe, J., Eriksson, B., Ottevald, J., Yang, Y. and Franzen, B. 2005. Extraction and proteomic analysis of proteins from bormal and multiple sclerosis post- mortem brain. J Chromatogr B Analyt Technol Biomed Life Sci, 815 , 191–202. Nilsson, P., Larsson, E.M., Maly-Sundgren, P., Perferkt, R. and Sandberg-Wollheim, M. 2005. Predicting the outcome of optic neuritis evaluation risk factors after 30 years of follow-up. J Neurol, 252, 396–402. Noseworthy, J.H., Lucchinetti, C., Rodriguez, M. and Weinshenker, B.G. 2000. Multiple sclerosis. N Engl J Med, 343, 938–52. Noseworthy, J., Miller, D. and Compston, A. 2005. Disease-modifying treatments in multiple sclerosis. In A. Compston, C. Confavreaux, H. Lassmann et al. (eds.), McAlpine’s Multiple Sclerosis, Churchill Livingston, London, pp. 729–802. O’Connor, P.W., Goodman, A., Willmer-Hulme, A.J. et al.; Natalizumab Multiple Sclerosis Trial Group. 2004. Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects. Neurology, 62(11), 2038–43. Oksenberg, J.R. and Barcellos, L.F. Multiple sclerosis genetics: Leaving no stone unturned. 2005. Genes Immunol, 6, 375–87. Oksenberg, J.R., Sherritt, M., Begovich, A.B. et al. 1989. T-cell receptor V alpha and C alpha alleles associated with multiple and myasthenia gravis. Proc Natl Acad Sci USA, 86, 988–92. Oksenberg, J.R., Barcellos, L.F., Cree, B.A. et al. 2004. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet, 74, 160–7. Olerup, O. and Hillert, J. 1991. HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation. Tissue Antigens, 38, 1–15. Omari, K.M., John, G.R., Sealfon, S.C. and Raine, C.S. 2005. CXC chemokine receptors on human oligo- dendrocytes: implications for multiple sclerosis. Brain, 128, 1003–15. Optic Neuritis Study Group. 1991. The clinical profile of acute optic neuritis: Experience of the Optic Neuritis treatment trial. Arch Ophthalmol, 109, 1673–8. Optic Neuritis Study Group. 1997. The 5-year risk of MS after optic neuritis: Experience of the Optic Neuritis Treatment Trial. Neurology, 49, 1404–13. Optic Neuritis Study Group. 2003. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the optic neuritis treatment trial. Arch Ophthalmol, 121, 944–9. Optic Neuritis Study Group. 2004. Neurologic impair- ment 10 years after optic neuritis. Arch Neurol, 61, 1386–9. Osterberg, A., Boivie, J. and Thomas, K. 2005. Central pain in multiple sclerosis – prevalence and clinical characteristics. Eur J Pain, 9, 531–42. Ozaki, I., Suzuki, C., Baba, M. and Matsunaga, M. 2003. Multiple sclerosis manifesting as a Brown–Sequard syndrome. Eur J Neurol, 10, 187–92. NICP_C03 04/05/2007 12:26PM Page 78 Multiple sclerosis 79 Pantano, P., Mainero, C. and Caramia, F. 2006. Func- tional brain reorganization in multiple sclerosis: Evidence from fMRI studies. J Neuroimaging, 16, 104–4. Paty, D.W. and Li, D.K. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology, 43, 662–7. Pettinelli, C.B. and McFarlin, D.E. 1981. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: Requirement for Lyt 1+ 2- T lymphocytes. J Immunol, 127, 1420–3. Pittock, S.J., McClelland, R.L., Mayr, W.T. et al. 2004. Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Ann Neurol, 56, 303–6. Pittock, S.J. McClelland, R.L. Achenbach, S.J. et al. 2005. Clinical course, pathologic correlations, and outcome of biopsy proved inflammatory demyelinat- ing disease. J Neurol Neurosurg Psychiatr, 76, 1693–7. Pittock, S.J., Weinshenker, B.G., Noseworthy, J.H. et al. 2006. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol, 63, 611–14. Paolino, E., Fainardi, E., Ruppi, P. et al. 1996. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neuro- logical syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry, 60, 572–5. Polman, C.H., Reingold, S.C., Edan, G. et al. 2005. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol, 58, 840–6. Polman, C.H., O’Connor, P.W., Havrdova, E. et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 354(9), 899–910. Poser, C.M. 1994. The dissemination of multiple sclerosis: a Viking saga? A historical essay. Ann Neurol, 36(S2), S231–43. Poser, C.M., Paty, D.W., Scheinberg, L. et al. 1983. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol, 13, 227–31. Prineas, J.W. Kwon, E.E. Cho, E.S. et al. 2001. Immuno- pathology of secondary-progressive multiple sclerosis. Ann Neurol, 50, 646–57. Pugliatti, M., Riise, T., Sotgiu, M.A. et al. 2005. Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia. Neuroepi- demiology, 25, 129–34. Raine, C.S. 1984. Biology of disease. Analysis of auto- immune demyelination: Its impact upon multiple sclerosis. Lab Invest, 50, 608–35. Rao, S.M., Leo, G.J., Bernardin, L. and Unverzagt, F. 1991. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology, 41, 685–91. Reddy, H., Narayanan, S., Arnoutelis, R. et al. 2000. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain, 123(11), 2314–20. Reiber, H. and Peter, J. 2001. Cerebrospinal fluid ana- lysis – disease-related data patterns and evaluation programs. J Neurol Sci, 184, 101–22. Reich, D., Patterson, N., Jager, P.L. et al. 2005. A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nat Genet, 37, 1113–18. Riordan-Eva, P., Sanders, M.D., Govan, G.G., Sweeney, M.G., Da Costa, J. and Harding, A.E. 1995. The clin- ical features of Leber’s hereditary optic neuropathy defined by the presence of a pathogenic mitochon- drial DNA mutation. Brain, 118, 319–37. Rivers, T.M. and Schwentker, F.F. 1935. Encephal- omyelitis accompanied by myelin destruction experi- mentally produced in monkeys. J Exp Med, 61, 689–702. Rodriguez, M., Karnes, W.E., Bartelson, J.D. and Pineda, A.A. 1993. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology, 43(6), 1100–4. Rosati, G., Aiello, I., Granieri, E. et al. 1986. Incidence of MS in Macomer, Sardinia, 1912–1981. Neurology, 36, 1419. Roth, M.P., Coppin, H., Descoins, P., Ruidavets, J.B., Cambon-Thomsen, A. and Clanet, M. 1991. HLA- DPB1 gene polymorphism and multiple sclerosis: a large case-control study in the southwest of France. J Neuroimmunol, 34, 215–22. Roth, M.P., Nogueira, L., Coppin, H., Clanet, M., Clayton, J. and Cambon-Thomsen, A. 1994. Tumor necrosis factor polymorphism in multiple sclerosis: no additional association independent of HLA. J Neuroimmunol, 51, 93–9. Rovaris, M., Agosta, F., Sormani, M.P. et al. 2003. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: A medium-term follow-up study. Brain, 126, 2323–32. Rovaris, M., Gallo, A., Valsasina, P. et al. 2005a. Short- term accrual of gray matter pathology in patients with progressive multiple sclerosis: An in vivo study using diffusion tensor MRI. Neuroimage, 24, 1139–46. Rovaris, M., Gass, A., Bammer, R. et al. 2005b. Diffusion MRI in multiple sclerosis. Neurology, 65, 1526–32. Roychowdhury, S., Maldjian, J.A. and Grossman, R.I. 2000. Multiple sclerosis: Comparison of trace apparent diffusion coefficients with MR enhance- ment pattern of lesions. AJNR Am J Neuroradiol, 21, 869–74. Rudick, R.A., Lee, J.C., Simon, J. and Fisher, E. 2006a. Significance of T2 lesions in multiple sclerosis: NICP_C03 04/05/2007 12:26PM Page 79 80 BERNADETTE KALMAN ET AL. A 13-year longitudinal study. Ann Neurol, 60(2), 236–42. Rudick, R.A., Stuart, W.H., Calabresi, P.A. et al. 2006b. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med, 354(9), 911–23. Sadovnick, A.D., Armstrong, H., Rice, G.P. et al. 1993. A population-based twin study of multiple sclerosis in twins: Update. Ann Neurol, 33, 281–5. Sadovnick, A.D., Bulman, D. and Ebers, G.C. 1991. Parent–child concordance in multiple sclerosis. Ann Neurol, 29, 252–5. Sadovnick, D.A., Yee, I., Ebers, G.C. and Risch, N.J. 1998. Effect of age at onset and parental disease status on sibling risks for MS. Neurology, 50, 719–23. Sadovnick, D.A., Yee, I.M., Ebers, G.C.; Canadian Collaborative Study Group. 2001. Recurrence risks to sibs of MS index cases: impact of consanguineous matings. Neurology, 56, 784–5. Sailer, M., O’Riordan, J.I., Thompson, A.J. et al. 1999. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology, 52, 599–606. Sandberg-Wollheim, M., Frank, D., Goodwin, T.M. et al. 2005. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology, 65(6), 802–6. Sanfilipo, M.P., Benedict, R.H., Sharma, J., Weinstock- Guttman, B. and Bakshi, R. 2005. The relation- ship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction. Neuroimage, 26, 1068–77. Sanfilipo, M.P., Benedict, R.H.B., Weinstock-Guttman, B. and Bakshi, R. 2006. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology, 66, 685–92. Sastre-Garriga, J., Ingle, G.T., Chard, D.T. et al. 2005. Grey and white matter volume changes in early primary progressive multiple sclerosis: A longitud- inal study. Brain, 128(6), 1454–60. Satoh, J., Nakanishi, M., Koike, F. et al. 2005. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis, 18, 537–50. Sawcer, S., Jones, H.B., Feakes, R. et al. 1996. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet, 13, 464–8. Seboun, E., Robinson, M.A., Doolittle, T.H., Ciulla, T.A., Kindt, T.J. and Hauser, S.L. 1989. A susceptibility locus for multiple sclerosis is linked to the T cell receptor β chain complex. Cell, 57, 1095–100. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. 2001. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology, 56(11), 1496–504. Schmidt, S., Barcellos, L.F., Desombre, K. et al.; Multiple Sclerosis Genetics Group. 2002. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet, 70, 708–17. Schmierer, K., Scaravilli, F., Altmann, D.R., Barker, G.J. and Miller, D.H. 2004. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol, 56, 407–15. Schumacher, F.A., Beeve, G.W. and Kibler, R.F. 1965. Problem of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci, 122, 552–68. Sharma, J., Jaisani, Z., Fabiano, A.J., Singh, B., Horsfield, M. and Bakshi, R. 2006. A magnetization transfer MRI study of deep gray matter involvement in multiple sclerosis. J Neuroimaging, in press. Sicotte, N.L., Voskuhl, R.R., Bouvier, S., Klutch, R., Cohen, M.S. and Mazziotta, J.C. 2003. Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol, 38, 423–7. Simon, J.H., Li, D., Traboulsee, A. et al. 2006. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol, 27, 455–61. Sipski, M.L., Rosen, R.C., Alexander, C.J. and Hamer, R.M. 2000. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology, 55(6), 812–15. Skegg, D., Corwin, P., Craven, R., Malloch, J.A. and Pollock, M. 1987. Occurrence of multiple sclerosis in the north and south of New Zealand. J Neurol Neurosurg Psychiatry, 50, 134–9. Smith, M.W., Patterson, N., Lautenberger, J.A. et al. 2004. A high-density admixture map for disease gene discovery in African Americans. Am J Hum Genet, 74, 1001–13. Snow, B.J., Tsui, J.K., Bhatt, M.H., Varelas, M., Hashimoto, S.A. and Calne, D.B. 1990. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol, 28(4), 512–15. Solaro, C., Lunardi, G.L., Capello, E. et al. 1998. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology, 51(2), 609–11. Srinivasan, R., Sailasuta, N., Hurd, R., Nelson, S. and Pelletier, D. 2005. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectros- copy at 3 T. Brain, 128, 1016–25. Stadelmann, C., Ludwin, S., Tabira, T. et al. 2005. Tissue preconditioning may explain concentric lesions in Balo’s type of multiple sclerosis. Brain, 128, 979–87. Stewart, G.J., Basten, A. and Kirk, R.L. 1979. Strong linkage disequilibrium between HLA-Dw2 and BfS in multiple sclerosis ad in normal population. Tissue Antigens, 14, 86–97. Stolp-Smith, K.A., Carter, J.L., Rohe, D.E. and Knowland, D.P. III. 1997. Management of impair- ment, disability, and handicap due to multiple sclerosis. Mayo Clin Proc, 72(12), 1184–96. Svendsen, K.B., Jensen, T.S., Hansen, H.J. and Bach, F.W. 2005. Sensory function and quality of life in NICP_C03 04/05/2007 12:26PM Page 80 Multiple sclerosis 81 patients with multiple sclerosis and pain. Pain, 114, 473–81. Tajouri, L., Mellick, A.S., Ashton, K.J. et al. 2003. Quantitative and qualitative changes in gene expres- sion patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res, 119, 170–83. Tartaglia, M.C. and Arnold, D.L. 2006. The role of MRS and fMRI in multiple sclerosis. Adv Neurol, 98, 185–202. The IFBN Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43(4), 655–61. The International SNP Map Working Group. 2001. A map of human genome sequence variation con- taining 1.42 million single nucleotide polymorphisms. Nature, 409, 928–33. The Multiple Sclerosis Genetics Group. 1996. A com- plete genomic screen for multiple sclerosis under- scores a role for the major histocompatibility complex. Nat Genet, 13, 469–71. The Transatlantic Multiple Sclerosis Genetics Cooper- ative. 2001. A meta-analysis of genomic screens in multiple sclerosis. Mult Scler, 7, 3–11. Transverse Myelitis Consortium Working Group. 2002. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology, 59, 499–505. Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick, R., Mork, S. and Bo, L. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med, 338, 278–85. Trapp, B.D., Ransohoff, R. and Rudick, R. 1999. Axonal pathology in multiple sclerosis: Relation- ship to neurologic disability. Curr Opin Neurol, 12, 295–302. Thompson, A.J., Montalban, X., Barkhof, F. et al. 2000. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol, 47, 831–5. Thompson, A.J., Jarett, L., Lockley, L., Marsden, J. and Stevenson, V.L. 2005. Clinical management of spasticity. J Neurol Neurosurg Psychiatry, 76, 459–63. Thronton, A.E. and Naftail, R. 1997. Memory impairment in multiple sclerosis: A quantitative review. Neuro- psychology, 11, 357–66. Tintore, M., Rovira, A., Martinez, M.J. et al. 2000. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol, 21, 702–6. Tourtellotte, W.W. 1970. Cerebrospinal fluid in multiple sclerosis. In P. Vinken and G.W. Bruyn (eds.), Handbook of Clinical Neurology, Vol. 9. North- Holland Publishing Co., Amsterdam, pp. 324–82. Trinchieri, G., Pflanz, S. and Kastelein, R.A. 2003. The IL-12 family of heterodimeric cytokines: New players in the regulation of T-cell responses. Immunity, 19, 641–4. Trip, S.A., Schlottmann, P.G., Jones, S.J. et al. 2005. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol, 58, 383–91. Valsasina, P., Benedetti, B., Rovaris, M., Sormani, M.P., Comi, G. and Filippi, M. 2005. Evidence for pro- gressive gray matter loss in patients with relapsing- remitting MS. Neurology, 65, 1126–8. van Buchem, M.A., Udupa, J.K., McGowan, J.C. et al. 1997. Global volumetric estimation of disease burden in multiple sclerosis based on magnetiza- tion transfer imaging. AJNR Am J Neuroradiol, 18, 1287–90. Vukusic, S., Hutchinson, M., Hours, M. et al.; Pregnancy In Multiple Sclerosis Group. 2004. Pregnancy and multiple sclerosis (the PRIMS study): Clinical predictors of post-partum relapse. Brain, 127, 1353–60. Vyshkina, T., Shugart, Y.Y., Birnbaum, G., Leist, T.P. and Kalman, B. 2005. Association of haplotypes in the β-chemokine locus with multiple sclerosis. Eur J Hum Genet, 13, 240–7. Vyshkina, T. and Kalman, B. 2005. Haplotypes within genes of β-chemokines are associated with multiple sclerosis: a second phase study. Hum Genet, 118, 67–75. Wallace, D.C., Singh, G., Lott, M.T. et al. 1988. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science, 242, 1427–30. Wandinger, K.P., Sturzebecher, C.S., Bielekova, B. et al. 2001. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol, 50, 349–57. Waubant, E., Alize, P., Tourbah, A. and Agid, Y. 2001. Paroxysmal dystonia (tonic spasm) in multiple sclerosis. Neurology, 57, 2320–1. Waxman, S.G. 2005. Cerebellar dysfunction in multiple sclerosis: Evidence for an acquired channelopathy. Prog Brain Res, 148, 353–65. Weinshenker, B.G., O’Brien, P.C., Petterson, T.M. et al. 1999. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol, 46(6), 878–86. Werring, D.J., Brassat, D., Droogan, A.G. et al. 2000. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain, 123(8), 1667–76. Werring, D.J., Clark, C.A., Barker, G.J., Thompson, A.J. and Miller, D.H. 1999. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology, 52, 1626–32. Wingerchuk, D.M. 2006. Multiple sclerosis disease- modifying therapies: adverse effect surveillance and management. Expert Rev Neurotherapeutics, 6(3), 333–46. Wingerchuk, D.M., Benarroch, E.E., O’Brien, P.C. et al. 2005. A randomized controlled crossover trial of NICP_C03 04/05/2007 12:26PM Page 81 82 BERNADETTE KALMAN ET AL. aspirin for fatigue in multiple sclerosis. Neurology, 65(7), 1267–9. Wood, N.W., Holmans, P., Clayton, D., Robertson, N. and Compston, D.A. 1994. No linkage or association between multiple sclerosis and the myelin basic pro- tein gene in affected sibling pairs. J Neurol Neurosurg Psychiatry, 57, 1191–4. Yednock, T.A., Cannon, C., Fritz, L.C., Sanchez-Madrid, F., Steinman, L. and Karin, N. 1992. Prevention of experimental allergic encephalomyelitis by anti- bodies against alpha 4 beta 1 integrin. Nature, 356, 63–6. Yousry, T.A., Major, E.O., Ryschkewitsch, C. et al. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med, 354(9), 924–33. Zein, G., Berta, A. and Foster, C.S. 2004. Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm, 12, 137–42. Zeman, A., McLean, B., Keir, G., Luxton, R., Sharief, M. and Thompson, E. 1993. The significance of serum oligoclonal bands in neurological diseases. J Neurol Neurosurg Psychiatry, 56, 32–5. Zenzola, A., De Mari, M., De Blasi, R., Carella, A. and Lamberti, P. 2001. Paroxysmal dystonia with thalamic lesion in multiple sclerosis. Neurol Sci, 22, 391–4. Zivadinov, R., Bagnato, F., Nasuelli, D. et al. 2004. Short-term brain atrophy changes in relapsing- remitting multiple sclerosis. J Neurol Sci, 223, 185–93. Zivadinov, R. and Bakshi, R. 2004a. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging, 14, S27–35. Zivadinov, R. and Bakshi, R. 2004b. Neurologic dis- ability and central nervous system atrophy in multiple sclerosis. In R. Zivadinov and R. Bakshi (eds.), Brain and Spinal Cord Atrophy in Multiple Sclerosis, Nova Biomedical Books, Hauppauge, NY, pp. 113–36. Zivadinov, R. and Bakshi, R. 2004c. Role of MRI in multiple sclerosis I: Inflammation and lesions. Front Biosci, 9, 665–83. Zivadinov, R. and Bakshi, R. 2004d. Role of MRI in multiple sclerosis II: Brain and spinal cord atrophy. Front Biosci, 9, 647–64. Zivadinov, R., Cookfair, D., Locatelli, L. et al. 2006. Interferon-beta-1a slows down progression of brain atrophy in relapsing-remitting multiple sclerosis by reducing predominantly grey matter atrophy pro- gression. Mult Scler, in press. Zivadinov, R. and Leist, T.P. 2005. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging, 15, 10S–21S. Zivadinov, R., Rudick, R.A., De Masi, R. et al. 2001a. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology, 57, 1239–47. Zivadinov, R., Sepcic, J., Nasuelli, D. et al. 2001b. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing- remitting multiple sclerosis. J Neurol Neurosurg Psychiatry, 70, 773–80. NICP_C03 04/05/2007 12:26PM Page 82 The association of a spinal cord disease and blindness was first reported by Albutt (1880). Eugene Dévic described his own patient with bilateral optic neuritis and myelitis, and reviewed 16 similar cases from the literature (Dévic, 1894). His student, Ferdinand Gault, summarized the available knowledge on the subject in his thesis (1894) and introduced the term neuromyelitis optica (NMO) that later also became known as Dévic’s disease. A great proportion of recent clinical and paraclinical studies of NMO was reported by investigators at the Mayo Clinic (Lennon et al., 2003, 2004, 2005; Lucchinetti et al., 2002; Pittock et al., 2005, 2006a,b; Wingerchuck et al., 1999, 2003, 2005, 2006). Clinical phenotype Prior to the availability of a biomarker, the question persisted as to whether the distinct clinical, magnetic resonance imaging (MRI), and pathological features of the NMO phenotype reflect a separate entity or rather a subtype within the spectrum of multiple sclerosis (MS). Clinically, patients with NMO present with isolated or simultaneous symptoms of optic neuritis (ON) and myelitis. The index events at nadir are usually associated with severe visual loss and/or paraplegia, sensory impairment, and loss of bowel and bladder control. Patients, who only have one index event at onset, typically develop all index events (myelitis and bilateral ON) within a few days to a few years. Reviewing medical records and MRI data between 1950 and 1993, and adding personal observations of patients between 1993 and 1997 at the Mayo Clinic, Wingerchuck et al. (1999) summarized demographics and clinical, laboratory, and MRI characteristics of NMO. Seventy-one predominantly Caucasian patients were retained in the analyses based on strict criteria (bilateral ON and myelitis, occurring within two years of one another without signs of disease outside of optic nerves and spinal cord) or not meeting strict criteria (unilateral ON or development of a second index event in more than two years). In this series, NMO presented with monophasic and relapsing pheno- types in 23 and 48 patients, respectively. The female to male ratio was close to 1:1 in the monophasic and 5:1 in the relapsing group. The median onset age of 29 years in the monophasic cohort was 10 years earlier than that in the relapsing cohort. While there was no difference in the rate of preceding viral illnesses or immunizations, 30% of patients with the relapsing form of NMO also had another autoimmune disorder. In relapsing NMO, optic neuritis or myelitis alone was the index event in 48% and 42% of cases, respect- ively, while 31% of patients with monophasic NMO presented with simultaneous bilateral optic neuritis and myelitis (Wingerchuck et al., 1999). The clinical severity of index events tended to be more severe at presentation and at recovery in the monophasic as compared to the relapsing form of NMO, but patients with the relapsing form also accumulated severe disability over time. Respiratory failure caused by cervical myelitis was noted 19 times in 16 relapsing patients and twice in two monophasic patients, and contributed to a 93% mortality rate in the relapsing group. The survival rate at five years was 90% in the monophasic and 68% in the relaps- ing group (Wingerchuck et al., 1999). Predictors of relapsing course included longer interattack intervals between the first two clinical (index) events, older age at onset, female gender, and less severe motor impairment with the myelitis. Mortality due to relapsing NMO was related to the history of other autoimmune disease, higher attack rate in the first two years, and a better motor recovery after the index myelitis (Wingerchuck and Weinshenker, 2003). The original Wingerchuck et al. (1999) criteria proposed that only clinical symptoms and imaging signs of lesions affecting the optic nerves/chiasm and the spinal cord (but not the brain) are compatible with the diagnosis of NMO. These clinical criteria 4 Dévic’s disease Bernadette Kalman NICP_C04 03/05/2007 10:35 AM Page 83 84 BERNADETTE KALMAN agreed with the opticospinal restriction of pathology emphasized by Mandler et al. (1993). However, in a more recent study using newer MRI and laboratory methods, Wingerchuck et al. (2005) found that 20% of their 84 patients with NMO also had neuro- logical symptoms suggesting disease outside of the optic nerves and spinal cord. Variables with high discriminative power included the NMO-IgG (see below) and distinct T2-weighted MRI features of the spinal cord lesion (see below) (Wingerchuck et al., 2005). The possible involvement of the central ner- vous system (CNS) in addition to lesions in the optic nerves and spinal cord was re-emphasized in the new NMO diagnostic criteria that incorporate the highly disease-specific NMO-IgG biomarker status (Wingerchuck et al., 2006). Cerebrospinal fluid characteristics In the acute cerebrospinal fluid (CSF), a moderate pleocytosis and increased proteins can usually be seen. The presence of oligoclonal bands (OCB) and elevated IgG index are less characteristic in NMO than in MS. In the survey by Wingerchuck et al. (1999), the median values of white blood cells were 12 and 28/mm 3 with 50% and 60% neutrophils in the monophasic and relapsing groups, respec- tively. Generally, >50 white blood cells/ml and >5 neutrophils/ml was proposed to support the diagnosis of NMO. The median CSF protein level was higher (84 mg/dl) in the relapsing as compared to the mono- phasic group (54 mg/dl). Elevated IgG index was detected in only 20% of each group, and OCBs were found in 43% and 33% of the monophasic and relaps- ing groups, respectively (Wingerchuck et al., 1999). MRI characteristics Imaging hallmarks of NMO are demonstrated in Fig. 4.1. Typically, a longitudinal cervical lesion (often affecting both the gray and white matter) extending across three or more vertebrae can be seen. Cord swelling and gadolinium enhancement occur in more than half of the patients. Cervical lesions may also extend into the medulla, the high thoracic region or even the entire cord, and eventually show signs of necrosis and cavitation. The diffuse enhance- ment of optic nerves and chiasm in acute stages is usually followed by atrophy in chronic stages of the disease (Wingerchuck et al., 1999). While the presence of cerebral lesions was previously considered incom- patible with the diagnosis of NMO (Wingerchuck et al., 1999), Pittock et al. (2005) found in a follow-up study of 60 patients that 50% of them also had positive brain MRI with nonspecific lesions in most, and with features suggestive of MS in 10%. A small subgroup (8%, mostly children) had atypical, conflu- ent cerebral hemispheral, brainstem or diencephalic (thalamic/hypothalamic) lesions, uncharacteristic of MS (Pittock et al., 2005). The revised diagnostic criteria reflect these observations (Wingerchuck et al., 2006). Magnetization transfer and diffusion tensor imaging techniques also revealed that micro- scopic pathology may be present in the normal appearing gray matter in the brain of patients with NMO (Rocca et al., 2004). Pathological characteristics A modern and comprehensive pathological evalua- tion of NMO was reported by Mandler et al. (1993) using hematoxylin-eosin, Luxol fast blue-hematoxylin, periodic acid-Schiff and Bodian’s silver staining. Five of the studied eight patients died between one and four years after the onset. The spinal cord was affected throughout most of its length. Microscopically, cavit- ation and necrosis were noted in both the gray and white matter. Necrotic lesions were associated with the presence of macrophages and prominent blood vessels. Vessel walls were thickened and hyalinized with scarce nuclei. The perivascular and parenchymal infiltrate included macrophages but no lymphocytes or plasma cells. The anterior optic pathway showed signs of demyelination, gliosis, and cavitation (Mandler et al., 1993). Using a panel of markers for immuno- histochemistry, Lucchinetti et al. (2002) characterized 82 lesions from nine autopsy cases of clinically definite NMO. All patients had extensive demyelination (a) (b) Fig. 4.1 MRI images of Dévic’s disease. The lesion extends across the entire cervical and upper thoracic cord with swelling of the cervical cord on the T2-weighted scan (a). The axial T1-weighted postgadolinium image (b) shows enhancement of the optic nerves. NICP_C04 03/05/2007 10:35 AM Page 84 Dévic’s disease 85 associated with cavitation, necrosis and acute axonal spheroids across multiple vertebral levels in both the gray and white matter. The depletion of oligodendrocytes was profound. In addition to macro- phages, large numbers of neutrophils and eosinophils were seen in acute parenchymal and meningeal infiltrates, with a rare appearance of CD3 and CD8 positive T cells. Striking deposition of immunoglobu- lins (mostly IgM) and complement C9 neoantigen was associated with vascular fibrosis and hyalinization in active and inactive lesions (Lucchinetti et al., 2002). The involvement of humoral immunity in the pathogenesis of NMO was further confirmed by demonstrating the increased numbers of myelin- oligodendrocyte glycoprotein (MOG)-specific B cells that produced increased amounts of IL-5, IL-6, IgG, and IgM in the CSF (Correale and Fiol, 2004). The number of IgM-secreting B cells was much higher than that of the IgG-producing cells. Chemokines chemoattractant for eosinophils were also increased in the CSF of patients with NMO. Genetics NMO presents as a sporadic disease and has been observed in both Caucasians and non-Caucasians. Nevertheless, its preferential occurrence in ethnic groups (i.e. Asians, Africans, Canadian Aboriginals, and French Afro-Caribbeans) with lower prevalence rates of typical MS was recognized (Cabre et al., 2001; Kuroiwa, 1985; Mirsattari et al., 2001; Misu et al., 2002; Osuntokun, 1981). While the relative risk for developing MS is 0.64 in African Americans (AA) compared to that in Caucasian Americans (CA), AAs are more likely to present with the opticospinal form or with transverse myelitis and have a more aggressive disease course than Caucasians (Cree et al., 2004). The DRB1*1501 and DRB5*0101 alleles associated with Western-type of MS are absent in patients with NMO or Asian-type of the disease in Japan (Kira et al., 1996). In contrast, these patients have an increased frequency of the HLA-DPB1*1501 allele (Yamasaki et al., 1999). Whole-genome admix- ture analyses using polymorphic markers in AA individuals aimed to differentiate chromosomal segments of African and European origin, and defined that 79% of the composite ancestry is African and 21% is European in origin. The association of MS with both the HLA-DRB1*1501 allele of Caucasian origin and the DRB1*1503 allele of African origin revealed that MS susceptibility was not simply related to the Northern-European gene influx into the AA population (Oksenberg et al., 2004). Genetic markers associated with the opticospinal disease in AA indi- viduals, however, remain to be identified. Full sequence analyses of mitochondrial DNA in three Caucasian NMO patients excluded the possibility that the necrotic nature of pathology was related to inherited point mutations or deletions in this extranuclear part of the genome (Kalman and Mandler, 2002). NMO-IgG, a biomarker for NMO In accordance with histological data, recent serolo- gical studies also add support to the involvement of a humoral mechanism by identifying a new immuno- globulin specific for NMO (Lennon et al., 2003). Sera from patients with NMO, MS, and other autoimmune disorders were used against mouse brain sections in an indirect immunofluorescence assay. A distinct IgG binding pattern associated with capillaries and the blood–brain barrier in the cerebellar cortex, midbrain, pia, and a subpial mesh (prominent in the midbrain) was noted in 54% of patients with NMO. This pattern of staining was also identified with sera from eight patients among several thousands screened in a blinded fashion at the Mayo Clinic. Breaking the code revealed that all these eight patients had definite or possible NMO. Follow-up studies using this assay confirmed a sensitivity of 83% and a specificity of 91% for NMO, and a sensitivity of 58% and specificity of 100% for the Asian form of opticospinal MS (Lennon et al., 2004). This study, thus, established that the NMO-IgG is a biological marker that distinguishes NMO from typical (or western-type of ) MS, and confirmed the immunolo- gical similarity between NMO and the Asian form of opticospinal MS. The NMO-IgG is positive in about 40% of longitudinally extensive transverse myelitis at the first event and predicts recurrence in 50% of patients in one year (Weinshenker et al., 2006). Lennon et al. (2005) recently identified the aquaporin-4 water channel as the antigenic target of NMO-IgG. Aquaporin-4 is a component of the dystroglycan protein complex located in the abluminal surface of blood vessels and the foot processes of astrocytes at the blood–brain barrier. Pittock et al. (2006a) observed in a subgroup of NMO patients that the dis- tribution of MRI abnormalities in the hypothalamic and periventricular areas corresponds to cereb- ral regions with high aquaporin-4 water channel expression. These findings raise the possibility that NMO may belong to a new class of autoimmune channelopathies and is biologically distinct from NICP_C04 03/05/2007 10:35 AM Page 85 [...]... and interleukins (IL) 10 and 6, each of which may be elevated 4 5 6 7 8 in cerebrospinal fluid (CSF), likely involved in pathogenesis IL-6 and TNF-α are likely proinflammatory and TNF-α may play a particular role in demyelination (Ichiyama et al., 2002) Disturbance of blood–brain barrier function is likely to be very important Lymphocytic perivenular in ammation is prominent Patchy perivenular demyelination... immunogenetically and clinically distinct disorders Ann Neurol, 40 , 569– 84 Kuroiwa, Y 1985 Neuromyelitis optica (Dévic’s disease, Dévic’s syndrome) In J.C Koetsier (ed.), Handbook of Clinical Neurology, Chapter 13 Elsevier, Amsterdam Lennon, V.A., Kryzer, T.J., Pittock, S.J., Verkman, A.S and Hinson, S.R 2005 IgG marker of optic-spinal multiple sclerosis binds to the aquaporin -4 water channel J Exp Med, 202, 48 3–8... radiographically including leukodystrophies, tumors, and infections CSF myelin basic protein concentration, usually positive in ADEM, may also be elevated in ONDs, including not only infections, but also tumors Rates of positivity of these tests as compared to clinically definite MS (CDMS), probable or possible MS (P/PMS), non-MS in ammatory illnesses (NMSI/I) or ONDs are shown in Table 5 .4 The EEG is abnormal... CDMS P/PMS ADEM NMSI/I OND CSF IgG/Albumin ratio CSF/Serum IgG index IgG synthetic rate Oligoclonal bands 60–80% 88– 94% 88–96% 83–100% 21– 24% 44 –55% 27–67% 24 89% 16–20% 15–20% 16–18% 10–12% 14 42 % 43 –57% 29% 27–72% 6–10% 3–18% 4 12% 2–29% NICP_C05 04/ 05/2007 12:26PM Page 95 Acute disseminated encephalomyelitis delta, or spikes may be found in the waking state during the early stages of as many as 2–7%... V.A., Lucchinetti, C.F and Weinshenker, B.G 2005 Neuromyelitis optica diagnostic criteria revisited: Validation and incorporation of NMO-IgG serum antibody Neurology, 64, A38 Wingerchuk, D.M and Weinshenker, B.G 2003 Neuromyelitis optica: Clinical predictors of a relapsing course and survival Neurology, 60, 848 –53 Yamasaki, K., Horiuchi, I., Minohara, M et al 1999 HLA-DPB1*0501-associated opticospinal multiple... experimental evidence (Levine and Wenk, 1965) However, changes of both AHLE and ADEM may develop in association with infectious encephalitis due to HSV, VZV, HHV6 and possibly other viruses Clinical settings in which AHLE has been found are listed in Box 5.13 Although cases do occur in adults, most postinfectious/post-vaccination cases of AHLE have occurred in young individuals (infancy to adolescence)... and in various laboratory results including cerebrospinal fluid (CSF) immune profile testing These CSF tests, shown in Box 5 .4, are of considerable importance in the evaluation of patients suspected of having MS, since approximately 95% of all individuals who have MS can be expected to show abnormalities of most or all of these tests upon their second clinical bout and thereafter Although CSF myelin basic... features that also distinguish ADEM from childhood-onset MS The absence of such abnormalities during the first bout of acute disseminated demyelinating illness in a child significantly increases the risk for ultimate MS diagnosis (Rust et al., 1989) EEG abnormalities are not found in adult ADEM (Hollinger et al., 2002) Imaging studies Focal low-density abnormalities are found in the brain computed tomography... found in deeper white matter, optic nerves, basal ganglia (30 40 %), thalamus (12 40 %), brainstem (45 –55%), cerebellum (30 40 %), and spinal cord Periventricular lesions (30 45 %) and corpus callosum lesions (10–15%) are much less common in childhood ADEM than in MS where they are so characteristic Various unusual lesions identified by MRI imaging in the nervous system of individuals with ADEM are listed in. .. helpful in distinguishing ADEM from alternative diagnoses (Hung et al., 2000; Takahashi et al., 1992) None of these approaches is likely to render a pathognomonic finding of ADEM or MS and diagnosis of ADEM should always rest on clinical grounds (Hollinger et al., 2002) Treatment Treatment of ADEM involves providing whatever support is indicated based upon the clinical circumstances In as many as 30 45 % . Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. 2001. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results 9, 647 – 64. Zivadinov, R., Cookfair, D., Locatelli, L. et al. 2006. Interferon-beta-1a slows down progression of brain atrophy in relapsing-remitting multiple sclerosis by reducing predominantly. multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43 (4) , 655–61. The International SNP Map Working Group. 2001. A map of human genome sequence variation con- taining 1 .42 million single nucleotide